MSMuhammed Sonmez

Muhammed Sonmez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammed Sonmez has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Selective Arterial Embolization for Renal Angiomyolipoma: A Giant Versus Non-Giant Lesion Subgroup Comparison

    by Mehmet Ali Durmus, Omer Faruk Topaloglu, Muhammed Sonmez, Sinan Taşdogan, Salih Demir, Haci Ibrahim Cimen, Mustafa Ozdemir, Volkan Tasci, Mahmud Islam, Onur Taydas, et al.

    Selective arterial embolization (SAE) is an established nephron-sparing option for renal angiomyolipoma (AML), but it remains unclear whether giant lesions (≥10 cm) respond less well or carry higher procedural risk. We retrospectively reviewed 40 patients treated with SAE between 2020 and 2025. Tris-acryl gelatin microspheres (300–500 µm) were the primary embolic agent; N-butyl cyanoacrylate or microcoils were added in 12 patients with acute bleeding or large aneurysms. Pre- and post-procedural values were compared with the Wilcoxon signed-rank test, and giant and non-giant lesions with the Mann–Whitney U and Fisher’s exact tests. Thirty-six patients (90%) were women, and 14 (35%) had giant lesions. Technical success reached 100% and clinical success 97.5% (39/40); no major complications occurred. Mean tumor diameter decreased by 13.6% (83.6 ± 47.2 vs. 72.7 ± 41.8 mm; p < 0.001), while estimated glomerular filtration rate (eGFR) did not change significantly (94.6 ± 21.6 vs. 87.7 ± 33.1 mL/min/1.73 m2; p = 0.203). Giant and non-giant lesions did not differ significantly in clinical success (92.9% vs. 100%; p > 0.999), shrinkage, or renal function (all p > 0.05). One patient with a giant, multifocal, tuberous sclerosis complex-associated lesion did not respond and underwent nephrectomy. These data suggest that tumor size alone may not preclude SAE.